Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers

被引：0

作者：

Henk van der Poel

Laurence Klotz

Gerald Andriole

Abdel-Rahmène Azzouzi

Anders Bjartell

Olivier Cussenot

Freddy Hamdy

Markus Graefen

Paolo Palma

Arturo Rodriguez Rivera

Christian G. Stief

机构：

[1] Netherlands Cancer Institute,Department of Urology

[2] University of Toronto,Division of Urology, Sunnybrook Health Science Centre

[3] Washington University St Louis,Division of Urology, Department of Surgery

[4] CHU d’Angers,Service d’Urologie

[5] Sahlgrenska Academy at the University of Gothenburg,Department of Urology, Institute of Clinical Sciences

[6] UPMC Univ Paris 06,Institute Universitaire de Cancerologie

[7] GRC-05,Nuffield Department of Surgical Sciences

[8] ONCOTYPE-Uro,Martini

[9] University of Oxford,Clinic Prostate Cancer Center

[10] University Medical Center Hamburg-Eppendorf,Department of Urology

[11] Universidade Estadual de Campinas,Department of Urology, Klinikum Großhadern, University Hospital Munich

[12] Hospital General Tlahuac,Großhadern

[13] Ludwig-Maximillians-University München,undefined

来源：

World Journal of Urology | 2015年 / 33卷

关键词：

Prostate cancer; Focal therapy; Active surveillance; Low risk; Intermediate risk; Consensus;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：907 / 916

页数：9

共 50 条

[21] Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance
Whalen, Michael J.
Pak, Jamie S.
Lascano, Danny
Ahlborn, David
Matulay, Justin T.
McKiernan, James M.
Benson, Mitchell C.
Wenske, Sven
CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : E425 - E435
[22] Management of low- and intermediate-risk prostate cancer
Henk van der Poel
Laurence Klotz
Christian G. Stief
World Journal of Urology, 2015, 33 : 905 - 906
[23] Management of low- and intermediate-risk prostate cancer
van der Poel, Henk
Klotz, Laurence
Stief, Christian G.
WORLD JOURNAL OF UROLOGY, 2015, 33 (07) : 905 - 906
[24] Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma
Jeong, Bae-Kwon
Jeong, Hojin
Ha, In Bong
Choi, Hoon Sik
Kam, Sung Chul
Hwa, Jeong Seok
Hyun, Jae Seog
Chung, Ky Hyun
Choi, See Min
Kang, Ki Mun
JOURNAL OF KOREAN MEDICAL SCIENCE, 2015, 30 (06) : 710 - 715
[25] Editorial Comment to "A national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer"
Matsumoto, Ryuji
INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (03) : 297 - 297
[26] Editorial Comment on a national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer
Kishida, Takeshi
INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (03) : 298 - 298
[27] Testosterone kinetics after proton therapy for low- and intermediate-risk prostate cancer
Nichols, Romaine Charles
Morris, Christopher G.
Hoppe, Bradford S.
Henderson, Randal H.
Mendenhall, William M.
Li, Zuofeng
Williams, Christopher R.
Costa, Joseph A.
Harris, Stephanie
Mendenhall, Nancy Price
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
[28] Is active surveillance safe for patients with intermediate-risk prostate cancer?
Chung, Hoseok
Shin, Bo Sung
Nam, Deok-Hyun
Chung, Hoseok
Kim, Myung Ki
Jung, Seung Il
Kang, Taek Won
Kwon, Dong Deuk
BJU INTERNATIONAL, 2015, 116 : 4 - 4
[29] Active surveillance for intermediate-risk prostate cancer: yes, but for whom?
Overland, Maya R.
Washington, Samuel L., III
Carroll, Peter R.
Cooperberg, Matthew R.
Herlemann, Annika
CURRENT OPINION IN UROLOGY, 2019, 29 (06) : 605 - 611
[30] Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low- to Intermediate-Risk Disease
Walser, Eric
Nance, Anne
Ynalvez, Leslie
Yong, Shan
Aoughsten, Jacqueline S.
Eyzaguirre, Eduardo J.
Williams, Stephen B.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2019, 30 (03) : 401 - 409

← 1 2 3 4 5 →